Amryt Pharma Holdings Ltd
LSE:AMYT
Intrinsic Value
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AMYT.
Amryt Pharma Holdings Ltd's market capitalization is 453.2m GBX.
AMYT stock price is 143 GBX.
AMYT.
AMYT. Open DCF Valuation
AMYT. Open Relative Valuation
AMYT.
AMYT has positive Net Debt. This means that the company has more debt (201m USD) than cash and short-term investments (123m USD).
AMYT's Revenue has grown by 11% over the past 12 months.
AMYT's ROIC (Return on Invested Capital) has increased in the last 3 years from -8% to -3%, and is approaching profitability.
AMYT's long-term assets (855m USD) exceed its long-term liabilties (549m USD).
AMYT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -3%.
AMYT's short-term assets (277m USD) exceed its short-term liabilties (154m USD).
AMYT's ROE (Return on Equity) has significantly increased in the last 3 years from -100% to -46%, and is approaching profitability.
AMYT's Revenue is forecast to grow at a rate of 30% per year over the next 3 years.
AMYT's D/E (Debt to Equity) is very low and is equal to 0.66.
AMYT has positive Gross Profit for the last twelve months.
AMYT has negative Operating Income for the last twelve months.
AMYT has negative Net Income for the last twelve months.
AMYT's ROE (Return on Equity) for the past 12 months is negative and is equal to -46%.
AMYT has negative Free Cash Flow for the last twelve months.
AMYT has negative three-year average ROE (Return on Equity): -46%. The company is not efficient at transforming stockholders' equity into net income.
AMYT has negative three-year average ROIC (Return on Invested Capital): -284%. The company is not efficient at using invested capital to generate operating income.
AMYT's Altman Z-Score is very low and is equal to 0.67.
AMYT doesn't generate enough operating income (-23m USD) to safely cover interest payments on its debt (12m USD).
Fundamental Analysis
Amryt Pharma Holdings Ltd
Balance Sheet Decomposition
Amryt Pharma Holdings Ltd
| Current Assets | 276.8m |
| Cash & Short-Term Investments | 123.2m |
| Receivables | 52.8m |
| Other Current Assets | 100.8m |
| Non-Current Assets | 578.7m |
| PP&E | 8.4m |
| Intangibles | 488.7m |
| Other Non-Current Assets | 81.5m |
| Current Liabilities | 153.8m |
| Other Current Liabilities | 153.8m |
| Non-Current Liabilities | 395.6m |
| Long-Term Debt | 200.6m |
| Other Non-Current Liabilities | 195m |
Earnings Waterfall
Amryt Pharma Holdings Ltd
|
Revenue
|
210.2m
USD
|
|
Cost of Revenue
|
-106.8m
USD
|
|
Gross Profit
|
103.4m
USD
|
|
Operating Expenses
|
-126.8m
USD
|
|
Operating Income
|
-23.3m
USD
|
|
Other Expenses
|
-64.2m
USD
|
|
Net Income
|
-87.5m
USD
|
Free Cash Flow Analysis
Amryt Pharma Holdings Ltd
AMYT Profitability Score
Profitability Due Diligence
Amryt Pharma Holdings Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Amryt Pharma Holdings Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
AMYT Solvency Score
Solvency Due Diligence
Amryt Pharma Holdings Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Amryt Pharma Holdings Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMYT Price Targets Summary
Amryt Pharma Holdings Ltd
Shareholder Return
AMYT Price
Amryt Pharma Holdings Ltd
| Average Annual Return | 62.99% |
| Standard Deviation of Annual Returns | 3.29% |
| Max Drawdown | -38% |
| Market Capitalization | 453.2m GBX |
| Shares Outstanding | 319 656 992 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Amryt Pharma Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.
You don't have any saved screeners yet
